Skip to search formSkip to main content

pimavanserin tartrate

Known as: bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate, urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) 
 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

Nuplazid
pimavanserinpimavanserin 17 MG Oral Tablet [Nuplazid]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Development of a UPLC–MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study
A simple, rapid and sensitive method based on an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
Parkinson's disease psychosis (PDP) is a common and often very disturbing component of Parkinson's disease (PD). PDP consists of… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
Erratum to: Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
Page 1093, Key Points box, The last point, which previously read: Newer agents are in development but comparative efficacy and… Expand
Is this relevant?
2016
2016
Reslizumab, ixekizumab, and pimavanserin tartrate.
 
Is this relevant?
Review
2014
Review
2014
New therapeutic agents marketed in 2013: Part 4
Objective: To provide information about the most important properties of new FDA-approved therapeutic agents marketed in 2016… Expand
  • table 1
Is this relevant?
2011
2011
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
OBJECTIVE Determine the effects of pimavanserin tartrate [ACP-103; N-(4-flurophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2… Expand
Is this relevant?
Review
2008
Review
2008
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
BACKGROUND Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced… Expand
Is this relevant?
2008
2008
Gateways to clinical trials.
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following… Expand
Is this relevant?
2008
2008
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced… Expand
Is this relevant?
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… Expand
Is this relevant?